Vagus Nerve Stimulation (VNS™) for Treatment-Resistant Depression Efficacy, Side Effects, and Predictors of Outcome

Sackeïm, Harold A.; Rush, A. John; George, Mark S.; Marangell, Lauren B.; Husain, Mustafa M.; Nahas, Ziad; Johnson, Christopher R.; Seidman, Stuart N.; Giller, Cole A.; Haines, Stephen J.; Simpson, Richard K.; Goodman, Robert

doi:10.1016/s0893-133x(01)00271-8

Cited by 477 publications

(266 citation statements)

References 43 publications

Supporting

Mentioning

242

Contrasting

Unclassified

Order By: Relevance

“…125,126 A single open study of VNS in 60 nonepileptic patients with treatment-resistant depression found a 31% response rate and 15% remission rate after 10 weeks. 127 These response and remission rates were sustained at 1 year 128 and improved at 2 years after surgery. 129 Based on these data, a large, sham-controlled study was conducted but failed to show statistically significant antidepressant effects for active VNS 130 ; at the end of the initial 10-week evaluation period, response rate was 15% with VNS and 10% with sham.…”

Section: Vagus Nerve Stimulationmentioning

confidence: 89%

Advances in the treatment of depression

Holtzheimer

Nemeroff

2006

NeuroRX

View full text Add to dashboard Cite

Summary: Depression is a highly prevalent and disabling condition associated with significant morbidity and mortality. Currently available treatments for depression include tricyclic antidepressants, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, various atypical antidepressants, and electroconvulsive therapy. Although these treatments are effective, a significant number of patients do not respond or achieve sustained remission despite aggressive management. Advances in the neurobiology of depression have suggested a number of novel targets for antidepressant treatment. Based on an improved understanding of the neurobiology of depression, several novel pharmacologic and nonpharmacologic interventions are being developed. Pharmacologic developments include CRF antagonists, glucocorticoid receptor antagonists, substance P receptor antagonists, NMDA glutamate receptor antagonists, transdermal selegiline, so-called "triple" reuptake inhibitors, and augmentation of typical antidepressant medications with atypical antipsychotics. Nonpharmacologic advances have largely involved focal brain stimulation techniques including vagus nerve stimulation, transcranial magnetic stimulation, magnetic seizure therapy, and deep brain stimulation. For the most part, the data on these treatments are preliminary, and more study is needed to clarify their potential clinical benefit. However, it is clear that further study of the neurobiology of depression will continue to provide a rationale for developing innovative targets for antidepressant therapies.

show abstract

Section: Vagus Nerve Stimulationmentioning

confidence: 89%

Advances in the treatment of depression

Holtzheimer

Nemeroff

2006

NeuroRX

View full text Add to dashboard Cite

show abstract

“…The cuff electrode is routinely used in the clinical setting for vagus nerve stimulation (VNS), which has been shown to be effective in the management of epilepsy [31,104], resistant depression [127], blood pressure control [110], as well as prevention of heart failure in patients with reduced ejection fractions [32,43,113]. Additionally, the Inspire® hypoglossal nerve stimulator, a Food and Drug Administration (FDA)- Fig.…”

Section: Cuff Electrodesmentioning

confidence: 99%

Interfacing with the nervous system: a review of current bioelectric technologies

et al. 2017

View full text Add to dashboard Cite

The aim of this study is to discuss the state of the art with regard to established or promising bioelectric therapies meant to alter or control neurologic function. We present recent reports on bioelectric technologies that interface with the nervous system at three potential sites-(1) the end organ, (2) the peripheral nervous system, and (3) the central nervous system-while exploring practical and clinical considerations.

show abstract

“…They are dose dependent and correlate with stimulation intensity and can be minimized with reductions in the stimulation parameters. Interestingly, most side effects decrease with time (Sackeim et al, 2001c). Hoarseness or voice alteration is the most persistent problem.…”

Section: Safetymentioning

confidence: 99%

“…In 1997 one of the authors (MSG), along with John Rush, Harold Sackeim, and later Lauren Marangell, began an initial pilot study of VNS for patients with treatmentresistant depression (TRD) Sackeim et al, 2001c). Several lines of evidence suggested that VNS might be helpful in patients with depression, including anecdotal reports of mood improvement in VNS implanted epilepsy patients and functional imaging studies showing that VNS increased activity in several regions of the brain thought to be involved with depression (Henry et al, 1998).…”

Section: Clinical Studiesmentioning

confidence: 99%

Noninvasive techniques for probing neurocircuitry and treating illness: vagus nerve stimulation (VNS), transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS)

George

Aston‐Jones

2009

Neuropsychopharmacol

312

196

View full text Add to dashboard Cite

Although the preceding chapters discuss much of the new knowledge of neurocircuitry of neuropsychiatric diseases, and an invasive approach to treatment, this chapter describes and reviews the noninvasive methods of testing circuit-based theories and treating neuropsychiatric diseases that do not involve implanting electrodes into the brain or on its surface. These techniques are transcranial magnetic stimulation, vagus nerve stimulation, and transcranial direct current stimulation. Two of these approaches have FDA approval as therapies.

show abstract

Vagus Nerve Stimulation (VNS™) for Treatment-Resistant Depression Efficacy, Side Effects, and Predictors of Outcome

Abstract: This open pilot study of vagus nerve stimulation (VNS ™ ) in 60 patients with treatment-resistant major depressive episodes (MDEs)

Cited by 477 publications

References 43 publications

Advances in the treatment of depression

Advances in the treatment of depression

Interfacing with the nervous system: a review of current bioelectric technologies

Noninvasive techniques for probing neurocircuitry and treating illness: vagus nerve stimulation (VNS), transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS)

Contact Info

Product

Resources

About